Release Date: March 20, 2007

Valid Through: March 19, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM

Fee: There is no fee for this activity

This CME activity is based on the following original summary articles:

ASCO GI 2007: Updates in the Treatment of Colorectal Cancer
Allyson Ocean, MD, Weill Medical College, Cornell University

Anemia and Gastrointestinal Cancer: Updates from ASCO GI 2007
C. Dean Buckner, MD, Founding Member, Fred Hutchinson Cancer Research Center

ASCO GI 2007: Patient Communication and Expectations
Allyson Ocean, MD, Weill Medical College, Cornell University

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the role of XELOX plus bevacizumab as initial therapy in the treatment of metastatic colorectal cancer.
• Explain the consistent  results involving panitumumab in heavily pre-treated patients with advanced colorectal cancer.
• Evaluate patient desires and physician beliefs regarding cytotoxic therapy in association with risk reduction of disease recurrence in patients with colorectal cancer.
• Discuss the potential role of oxaliplatin in addition to 5-fluorouracil in the treatment of rectal cancer.
• Consider results of different schedules and dosing of darbepoetin alfa and epoetin alfa and their effects on chemotherapy-induced anemia.

Disclaimer
Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters
This activity is supported by an educational donation provided by Amgen.